Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 28, 2014; 20(32): 11142-11159
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11142
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11142
Therapeutic option | Subset | Ref. |
Surgical resection | Cephalic pancreatoduodenectomy Distal pancreatectomy Total pancreatectomy | Hidalgo[41] |
Chemotherapy | Neoadjuvant Gemcitabine Adjuvant Gemcitabine 5-Fluorouracil Advanced disease Gemcitabine Gemcitabine + fluropyrimidines Gemcitabine + platinum analogs Gemcitabine + erlotinib FOLFIRINOX Nab-paclitaxel | Lemmens et al[101]; Gillen et al[102]; Neoptolemos et al[108]; Burris et al[118]; Heinemann et al[119]; Reni et al[120]; Moore et al[122]; Neesse et al[79] |
Radiation therapy | Neoadjuvant Radiation + 5-fluorouracil Radiation + paclitaxel Proton beam radiation + capecitabine Adjuvant Radiation + 5-Fluorouracil Radiation + gemcitabine Radiation + chemotherapy Advanced Radiation + 5-fluorouracil Radiation + chemotherapy Stereotactic body radiotherapy | Pisters et al[131]; Hong et al[133]; Yeo et al[140]; Regine et al[138]; Neoptolemos et al[137]; Moertel et al[144]; Schellenberg et al[147] |
Personalized therapy | Target specific point mutations Mitomycin C Immune system stimulation | Jones et al[77]; Villarroel et al[153]; Yanagimoto et al[154] |
- Citation: Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159
- URL: https://www.wjgnet.com/1007-9327/full/v20/i32/11142.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i32.11142